Multidisciplinary Treatment of Prostate Cancer
Optimal treatment of prostate cancer requires a multidisciplinary team approach, with expertise needed in medical oncology, radiation oncology, urology, genetics, pathology, diagnostic radiology, and supportive care. It is important for clinicians who treat patients with prostate cancer to understand all facets of comprehensive care so that their patients receive the best possible treatments with effective management of side effects.
Target Audience
This educational program is designed to meet the educational needs of physicians, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.
Learning Objectives
Following this program, participants should be able to:
- Provide an overview of the treatments used to treat patients with prostate cancer
- Discuss the roles that genetics and diagnostic radiology professionals play in the optimal management of prostate cancer
- Understand management strategies for supportive care issues in patients with prostate cancer
Anthony V. D'Amico, MD, PhD
Dana-Farber/Brigham and Women's Cancer Center
Tanya Dorff, MD
City of Hope National Medical Center
Edward Schaeffer, MD, PhD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter.
Definitions
NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.
NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Faculty Disclosures
The faculty listed below discloses no relevant financial relationships:
Anthony V. D'Amico, MD, PhD
The faculty listed below discloses the following relevant financial relationships:
Tanya Dorff, MD
AbbVie, Inc.: Consulting Fee
Bayer HealthCare: Consulting Fee
Exelixis Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
Edward Schaeffer, MD, PhD
Janssen Scientific Affairs, LLC: Scientific Advisor
Pfizer Inc.: Scientific Advisor
NCCN Staff Disclosures
The NCCN Leadership listed below discloses no relevant financial relationships:
Wui-Jin Koh, MD
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Mike Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Deborah A. Freedman-Cass, PhD; Dorothy A. Shead, MS
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.
Pharmacists
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-21-047-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until March 1, 2022. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing